Tag: Squibb
Bristol Myers Squibb benefits from the success of its anemia products
(AOF) – Bristol Myers Squibb is expected to rise in pre-market on Wall Street after forgetting better than expected results for the fourth quarter. The American pharmaceutical group posted adjusted…
Bristol Myers Squibb: FDA to review data
(CercleFinance.com) – Bristol Myers Squibb and 2seventy bio provide update on US FDA review of SBLA for abecca (idecabtagene vicleucel) in earlier lines of treatment for exposed relapsed or refractory…
Bristol Myers Squibb expected to decline after postponement of its turnover targets
(AOF) – Bristol Myers Squibb is expected to decline in pre-market trading on Wall Street after having postponed by one year, from 2025 to 2026, its objective of exceeding $10…
Bristol Myers Squibb buys biotech Mirati
(AOF) – Bristol Myers Squibb announced the acquisition of the American biotech Mirati for $58.00 per share, representing a net value of $4.8 billion and up to $5.8 billion, while…
Bristol Myers Squibb: FDA Approved Production Site
(CercleFinance.com) – Bristol Myers Squibb announced yesterday that the US Food and Drug Administration (FDA) has approved commercial production at the company’s brand new cell therapy production site in Devens,…
Faced with the loss of monopoly of its star drug, Bristol-Myers Squibb remains confident
Outside of industry specialists, his name is unknown. Yet, in the pharmaceutical industry, Revlimid is a superstar. This cancer drug, used in particular in the treatment of patients with multiple…